Skip to main content

The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government

UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to the PROTECT-V trial – a platform study investigating UNION’s niclosamide-based treatment candidate for COVID-19 in kidney patients.


Union

Clinical trials granted UPH prioritization by the NIHR are deemed critically important in the fight against COVID-19 and will thus receive infrastructure support allowing expedited recruitment for the study. NIHR is an entity under the Department of Health & Social Care of the UK government.

UPH prioritization will enable streamlined site set up across the UK, and facilitate rapid patient recruitment as a result of NIHR resource and clinical research network support being available.

The PROTECT-V trial is led by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge and involves researchers and patients from across the UK.

For more information visit: UNION Therapeutics

Published March 29 2021

Latest from CCTU

New clues about irritable bowel syndrome found in the brain

Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.

Researchers eye up new gene therapy trial that could reverse hereditary blindness

Restoration of sight from a rare genetic mutation may now become a reality thanks to a prestigious award from the National Institute for Health Research (…

Artificial pancreas trialled for outpatients with type 2 diabetes for first time

An artificial pancreas could soon help people living with type 2 diabetes and who also require kidney dialysis.

All news